Clinical Trial Update: Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating rectal misoprostol as a hemostatic agent during abdominal myomectomy to reduce surgical blood loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• MISOPROSTOL (Misoprostol)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Myomectomy; Surgical Blood Loss | Phase 4 | Status: COMPLETED | Results posted: 2025-07-29